Antipsychotic Drug Use
Among Kids Soars
Report raises concerns that mind-altering pills are
being overprescribed
(May 3, 2006) -- The number of children taking
antipsychotic medicines soared 73 percent in the four years ending in
2005, far outpacing the increase in adults, according to a Medco Health
Solutions Inc. report released Tuesday.
Use of the new class of drugs known as atypical antipsychotics by people
19 and younger skyrocketed 80 percent in the same time period, according to
the pharmacy benefit manager.
Antipsychotic drug prescriptions for that age group comprise a relatively
small amount of the total for such medicines, Medco said. In 2005, 15
percent of prescriptions for such drugs were for children while 85 percent
were for adults.
Still, the sharp increase is noteworthy because the powerful drugs are
for individuals with serious psychosis such as
schizophrenia so there is some concern the medicines may not always be
prescribed appropriately, said Dr. Amita Dasmanapatra, senior director of
medical affairs at Medco. She said it is possible that some doctors are
prescribing the drugs for
children with behavioral problems, which would be better controlled by
other means. Medco's analysis of over 2 million insured Americans didn't
explore the reasons for the increase.
Additionally, the atypical antipsychotics aren't approved for use in
children although doctors are free to prescribe drugs as they see fit.
The number of children on antipsychotics rose to 6.6 per 1,000 in 2005
from 3.81 per thousand in 2001. In contrast, 11 adults per 1,000 were taking
one of the drugs. The increase in the number of adults taking antipsychotics
rose 13 percent in the four years ended in 2005.
However, the rate of prescription growth in children has been slowing
although the analysis was not designed to determine the reason. For example,
the rate of prescription growth in all antipsychotics was 3.38 percent last
year, down from 14 percent in 2004 and 22 percent in 2003. Meanwhile, last
year prescription growth for atypical antipsychotics was nearly 5 percent,
down from nearly 13 percent in 2004 and 24 percent in 2003.
Dr. David Kessler, a child and adolescent psychiatrist in Burlington, Vt.,
speculated that the decrease in growth is tied to concern about atypical
antipsychotics link to diabetes.
In 2003, The U.S. Food and Drug Administration asked manufacturers of
atypical antipsychotics to add warning labels describing the increased risk
of high blood sugar and diabetes. The drugs include Eli Lilly & Co.'s
Zyprexa, AstraZeneca PLC's Seroquel, Bristol-Myers Squibb Co.'s Abilify and
Pfizer Inc.'s Geodon.
Also, last year the FDA determined that elderly patients with dementia
that were being treated with atypical antipsychotics had an increased risk
of death. The FDA asked manufacturers to include a warning on the drugs'
label about the risk, and note that the drugs are not approved to treat
behavioral problems in patients with dementia.
Sources: Medco Health Solutions Inc. and Associated Press
Last updated: 05/06
Related Information:
back to
top ~ bipolar news index ~
send page to a
friend |